Bharat Parenterals Limited Schedules Board Meeting on May 18, 2026 to Approve FY26 Financial Results

Bharat Parenterals Limited has notified the BSE of an upcoming Board of Directors meeting scheduled for Monday, May 18, 2026. The intimation was filed on May 09, 2026, pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, from its registered office located at Survey No. 144-A, Jarod-Samlaya Road, Village Haripura, Ta. Savli, Dist. Vadodara – 391520, Gujarat.

Agenda of the Board Meeting

The board meeting has been convened to address several key corporate and financial matters. The following items are on the agenda for consideration:

Agenda Item:	Details
Financial Results:	Audited Standalone & Consolidated Financial Results for Q4 and year ended March 31, 2026
Financial Statements:	Audited Standalone & Consolidated Financial Statements for FY ended March 31, 2026
Dividend Consideration:	Recommendation of final dividend, if any, on equity shares for FY ended March 31, 2026
Other Business:	Any other business placed before the board with the permission of the Chairman

Trading Window Closure

In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons and their immediate relatives, the Trading Window for dealing in the company's securities has been closed. The closure came into effect from Wednesday, April 1, 2026, and will remain in force until 48 hours after the declaration of the financial results.

The intimation was signed by Sharmin Soni, Company Secretary & Compliance Officer (ICSI M. No: A-75694), on behalf of Bharat Parenterals Limited.

Bharat Parenterals Limited has issued a formal disclosure to BSE Limited regarding newspaper advertisements published on April 29, 2026, concerning proposed share transfers in physical form. The disclosure was made under Regulation 30 of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.

Regulatory Compliance and SEBI Circular

The company published advertisements pursuant to SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026, which allows the opening of a special window for re-lodgement of transfer of shares in physical form. This regulatory framework enables shareholders to complete pending share transfer processes that were previously restricted.

Publication Details

The advertisements were published in two newspapers to ensure comprehensive reach:

Publication Type:	Details
English Newspaper:	Business Standard
Regional Newspaper:	Vadodara Samachar (Gujarati)
Publication Date:	April 29, 2026
Website Availability:	www.bplindia.in

Company Information and Certifications

Bharat Parenterals Limited operates as a WHO-GMP certified pharmaceutical company with Star Export House status. The company is headquartered at Survey No. 144-A, Jarod-Samlaya Road, Village Haripura, Taluka Savli, District Vadodara, Gujarat. The disclosure was signed by Sharmin Soni, Company Secretary and Compliance Officer (ICSI M. No: ACS-75694).

Share Transfer Process

The advertisement provides detailed information about proposed share transfers, including specific shareholder names, addresses, security numbers, and certificate details. The SEBI circular facilitates the completion of physical share transfers that may have been pending due to previous regulatory restrictions.

The company has ensured compliance with disclosure requirements by making the information available through multiple channels, including newspaper publications and its official website, thereby maintaining transparency with stakeholders and regulatory authorities.